INSYS Therapeutics Receives Complete Response Letter from FDA for Buprenorphine NDA
27 juil. 2018 12h50 HE
|
INSYS Therapeutics, Inc.
PHOENIX, July 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)...
INSYS Therapeutics to Report Second Quarter 2018 Results on Aug. 8
25 juil. 2018 08h00 HE
|
Insys Therapeutics, Inc.
PHOENIX, July 25, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
INSYS Therapeutics Provides an Update on Its Ongoing Transformation
18 juin 2018 12h58 HE
|
Insys Therapeutics, Inc.
PHOENIX, June 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection
14 juin 2018 08h00 HE
|
Insys Therapeutics, Inc.
PHOENIX, June 14, 2018 (GLOBE NEWSWIRE) -- Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option...
INSYS Therapeutics to Present at Jefferies Global Healthcare Conference
04 juin 2018 16h15 HE
|
Insys Therapeutics, Inc.
PHOENIX, June 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray
22 mai 2018 15h08 HE
|
Insys Therapeutics, Inc.
PHOENIX, May 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts
15 mai 2018 12h23 HE
|
Insys Therapeutics, Inc.
PHOENIX, May 15, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East
08 mai 2018 16h02 HE
|
Insys Therapeutics, Inc.
PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
INSYS Therapeutics Reports First Quarter 2018 Results
08 mai 2018 16h00 HE
|
Insys Therapeutics, Inc.
Cannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS® revenue continue PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc....
INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome
27 avr. 2018 08h00 HE
|
Insys Therapeutics, Inc.
PHOENIX, April 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...